文献速递造血干细胞移植与细胞治疗

造血干细胞移植建立的混合嵌合由受者与供者调节性T细胞共同维持

Mixed chimerism established by hematopoietic stem cell transplantation is maintained by host and donor T regulatory cells.
PubMed 文献 · Blood Adv · 2019-01-01

研究纳入69例造血干细胞移植后2个月内患者,其中37例为完全供者嵌合、32例为混合嵌合。混合嵌合期间Treg细胞比例升高且供者与受者来源各占一半,伴随树突细胞PD-L1+耐受表型;混合嵌合患者效应T细胞对受者靶细胞体外细胞毒性降低,去除CD4+ Treg后恢复。

要点

  • 移植后2个月内32例混合嵌合患者Treg比例升高,供者与受者来源各半。
  • 混合嵌合伴随树突细胞PD-L1+耐受表型。
  • 混合嵌合患者效应T细胞体外杀伤受者靶细胞降低,去除CD4+ Treg后恢复。

核心结论

  • Treg细胞在混合嵌合期间维持免疫耐受中起主要作用,这些认识应有助于指导改进临床移植的新干预措施。

研究设计与样本

  • 研究分析了69例造血干细胞移植后2个月内的患者免疫功,其中37例为完全供者嵌合、32例为混合嵌合。

主要发现

  • 混合嵌合期间Treg细胞比例升高,由供者与受者来源调节性细胞等量组成。
  • 混合嵌合与树突细胞PD-L1+耐受性表型相关。
  • 混合嵌合患者效应T细胞对受者靶细胞的体外细胞毒性降低,去除CD4+ Treg细胞后该细胞毒性恢复。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transplantation is an effective treatment of many clinical disorders, but the mechanisms that regulate immunological tolerance are uncertain and remain central to improving patient outcome. Hemopoietic stem cell transplantation (SCT) often establishes "mixed chimerism" in which immune cells from both the donor and patient coexist in vivo in a setting of immunological tolerance. We studied immune function in 69 patients within 2 months following SCT; 37 were fully donor and 32 displayed mixed chimerism. The proportion of T regulatory (Treg) cells was increased during mixed chimerism and comprised equal numbers of donor and host-derived regulatory cells. This was associated with a tolerogenic PD-L1+ profile on dendritic cells. Importantly, effector T cells from patients with mixed chimerism exhibited reduced cytotoxicity against host target cells in vitro, but this was restored following depletion of CD4+ Treg cells. These data show that Treg cells play a major role in sustaining immunological tolerance during mixed chimerism. These insights should help to guide novel interventions to improve clinical transplantation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kinsella FAM, Zuo J, Inman CF, et al. Mixed chimerism established by hematopoietic stem cell transplantation is maintained by host and donor T regulatory cells. Blood Adv. 2019. PMID: 30824417. doi:10.1182/bloodadvances.2018025502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。